辛帕奈单抗治疗早期帕金森病:2期SPARK临床试验生物标志物结果评估
SPARK是一项随机、双盲、安慰剂对照的2期多中心试验,评估辛帕奈单抗治疗早期帕金森病的疗效与生物标志物。研究纳入357例病程3年内的患者,每4周静脉给药共52周。结果显示临床疾病有进展,但辛帕奈单抗组与安慰剂组在生物标志物上无统计学显著差异,试验因缺乏疗效而终止。
要点
- SPARK试验因辛帕奈单抗缺乏疗效而终止,生物标志物 measures 未见显著治疗效应。
- 约93%(110/118)的脑脊液亚组患者在基线时α-突触核蛋白种子阳性,52周时99%仍阳性。
- 各生物标志物年变化微小且个体间变异大,同侧壳核纹状体结合比的平均变化最大。
核心结论
- 生物标志物结果显示入组的是预期的早期帕金森病人群,但生物标志物与疾病进展无显著相关性,也无明确证据表明辛帕奈单抗对生物标志物有治疗效应。
研究设计与样本
- SPARK为随机、双盲、安慰剂对照的2期多中心试验,评估3种辛帕奈单抗剂量每4周静脉给药52周,并设活性治疗剂量盲法扩展期长达112周。
- 试验纳入357例40-80岁、病程3年内、改良Hoehn和Yahr量表≤2.5分且纹状体多巴胺能缺陷证据的帕金森病患者。
- 试验于2018年1月至2021年4月进行,因缺乏疗效而终止。
主要发现
- 约3.8%(15/398)接受SPECT成像的参与者无多巴胺能缺陷证据而被筛选失败。
- 基线时93%(110/118)的入组脑脊液亚组被二分类法判定为α-突触核蛋白种子阳性。
- 观察到临床疾病进展,但辛帕奈单抗组与安慰剂组相比无统计学显著差异。
- 52周时99%的α-突触核蛋白种子阳性参与者仍为阳性。
- 各生物标志物指标在治疗组与安慰剂组间从基线到52周的变化均无统计学显著差异,年变化微小且个体间变异大,同侧壳核纹状体结合比的平均变化/标准差随时间最大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Sensitive, reliable, and scalable biomarkers are needed to accelerate the development of therapies for Parkinson disease (PD). In this study, we evaluate the biomarkers of early PD diagnosis, disease progression, and treatment effect collected in the SPARK. METHODS: Cinpanemab is a human-derived monoclonal antibody binding preferentially to aggregated forms of extracellular α-synuclein. SPARK was a randomized, double-blind, placebo-controlled, phase 2 multicenter trial evaluating 3 cinpanemab doses administered intravenously every 4 weeks for 52 weeks with an active treatment dose-blind extension period for up to 112 weeks. SPARK enrolled 357 participants diagnosed with PD within 3 years, aged 40-80 years, ≤2.5 on the modified Hoehn and Yahr scale, and with evidence of striatal dopaminergic deficit. The primary outcome was change from baseline in the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale total score. Secondary and exploratory biomarker outcomes evaluated change from baseline at week 52 relative to placebo. Dopamine transporter SPECT and MRI were used to quantify changes in the nigrostriatal dopamine pathway and regional atrophy. CSF and plasma samples were used to assess change in total α-synuclein levels, α-synuclein seeding, and neurofilament light chain levels. SPARK was conducted from January 2018 to April 2021 and terminated due to lack of efficacy. RESULTS: Approximately 3.8% (15/398) of SPECT-imaged participants did not have evidence of dopaminergic deficit and were screen-failed. Binary classification of α-synuclein seeding designated 93% (110/118) of the enrolled CSF subgroup as positive for α-synuclein seeds at baseline. Clinical disease progression was observed, with no statistically significant difference in cinpanemab groups compared with that in placebo. Ninety-nine percent of participants with positive α-synuclein seeding remained positive through week 52. No statistically significant changes from baseline were observed between treatment groups and placebo across biomarker measures. Broadly, there was minimal annual change with high interindividual variability across biomarkers-with striatal binding ratios of the ipsilateral putamen showing the greatest mean change/SD over time. DISCUSSION: Biomarker results indicated enrollment of the intended population with early PD, but there was no significant correlation with disease progression or clear evidence of a cinpanemab treatment effect on biomarker measures. Suitable biomarkers for evaluating disease severity and progression in early PD trials are still needed. TRIAL REGISTRATION INFORMATION: NCT03318523 (clinicaltrials.gov/ct2/show/NCT03318523); Submitted October 24, 2017; First patient enrolled January 2018.
引用
- Hutchison RM, Fraser K, Yang M, et al. Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. Neurology. 2024. PMID: 38315945. doi:10.1212/WNL.0000000000209137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。